Ga acorn final


GlobalAcorn innovates and develops novel advanced therapeutics from laboratories to phase IIA clinical studies.

  • Stage Concept Only
  • Industry Biotechnology
  • Location London, GB-ENG, United Kingdom
  • Currency GBP
  • Founded March 2010
  • Website

Company Summary

GlobalAcorn is a cancer nanomedicine biopharmaceutical company dedicated to discovering and developing advanced therapeutics and diagnostics intended to transform the standard of care in treating and managing cancer. Our Lipid-based nanoparticle technologies are designed with specific physical and chemical characteristics that make possible high levels of control over, directing and release of pharmaceutical agents to disease target sites


  • Default avatar
    Jeremy Curnock Cook

    Mr Jeremy Curnock Cook is an experienced entrepreneur, fund manager, executive and non-­executive director in the life science sector. He is currently Executive Chairman of International Bioscience Managers Limited and also the Non‐Executive Director of Phylogica, a leading Australian peptide drug discovery company. Over his 40-year career, he has served on 40 Boards in various roles, including Chairman, of private and public companies.

  • E7fbd6b7 1102 4e87 b93d c8ae75e71890
    Chief Executive Officer

    Over 25 years working in the pharmaceutical and biotechnology industry
    In the last decade successfully focused on bringing products from the lab to the market . At Adamas (ADMS) he was a co-inventor of core Alzheimer therapy to be launched in 2015. Adamas now has a current market value of $248mio (November 2014).

  • Default avatar
    Prof Andrew Miller
    Chief Scientist Officer, Co-Founder

    UK’s leading expert in organic chemistry and chemical biology. Key founding director of the UK’s first Genetic Therapies Centre. GTC also focused on lipid-based nanoparticle delivery systems thus making Andrew a leading expert in this field. GlobalAcorn development and discovery pipelines all derive from academic research carried out exclusively by Prof Miller and key collaborators since 1993, involving a research spend in excess of $30million

  • Ffc1877e db70 4dfb a560 0849c1a3f237
    Chief Financial Officer

    Silvia was previously a European Small Cap Fund manager for over 10 years in London, managing over £1bn in assets for institutional and retail clients. Silvia has an MBA in Finance from Nottingham University in UK, and a Business degree from University of Augsburg, Germany.

  • Default avatar
    Dr Shoona Vincent
    Head of Clinical Development

    Dr. Vincent has over 20 years of pharmaceutical industry experience in clinical research and development and has implemented and managed over
    10 INDs, several NDAs, MAAs and lead clinical development programs for several global pharmaceutical companies. His responsibilities included strategic leadership from nonclinical to clinical development and regulatory strategy.

  • Default avatar
    Dr. Nigel Whittle
    Head of Commercial Development

    Dr Whittle has more than 25 years’ experience in the biotechnology sector, as an R&D scientist with organizations such as Genentech, Celltech and Cantab Pharmaceuticals, and more recently as a business development specialist with consulting firms, private equity organizations and UK Trade & Investment, with a focus on international investment in life sciences.

  • 37bb51eb c1b3 4f04 94ad 6c3aca412ff7
    Head of Pre-Clinical Development

    Dr. Brody obtained her PhD at Imperial College London in nanomedicine. She was previously at the Broad Institute in the RNAi Consortium (TRC) and Abgent, Inc. She holds a BSc in Biochemistry from Simmons College.